Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 45, Issue 12, Pages 2362-2365Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm025522z
Keywords
-
Categories
Ask authors/readers for more resources
Dipeptidyl peptidase IV (DPP-IV) inhibition has the potential to become a valuable therapy for type 2 diabetes. We report the first use of solid-phase synthesis in the discovery of a new DPP-I-V inhibitor class and a solution-phase synthesis that is practical up to the multikilogram. scale. One compound, NVP-DPP728 (2), is profiled as a potent, selective, and short-acting DPP-I-V inhibitor that has excellent oral bioavailability and potent antihyperglycemic activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available